The 1.3 trillion dollar biopharmaceutical industry is at a crossroads. The pandemic has done at least two things to our commercial model: first, it accelerated our shift to a sophisticated digital presence, and, second, it has changed message consumption preference of our health care professionals.
Frank Dolan and Hans Kaspersetz, Chief Innovation Officer at Relevate Health, explore what’s possible for life science brands.
There’s a window of opportunity for brands to rethink strategy, leverage data in new ways, and find themselves, at least their brands, standing in plain sight right where the customer needs them. Watch the session to learn how.
Hans is a thought leader in life science brand strategy. Often quoted at industry conferences, Hans has been involved in numerous biopharma brands helping them through brilliant strategy and the latest technology to unlock brand potential.